Rheumatology:AS疲劳评价需重视其频率和严重性

2014-03-27 佚名 丁香园

与其他慢性疾病如类风湿关节炎相比,疲劳是强直性脊柱炎(AS)疾病症状更为重要的组成部分。高达66%的AS患者遭受疲劳感的折磨,而目前对AS患者疲劳感的评价过于单一。鉴于此,来自英国华威大学的Kirstie L. Haywood等人在AS患者中探讨疲劳的频率和严重性以及相互间的关系,评价其对病情判断的价值和意义。研究结果发表在2014年3月的Rheumatology上。 在基线期,将参与者按照疲劳

与其他慢性疾病如类风湿关节炎相比,疲劳是强直性脊柱炎(AS)疾病症状更为重要的组成部分。高达66%的AS患者遭受疲劳感的折磨,而目前对AS患者疲劳感的评价过于单一。鉴于此,来自英国华威大学的Kirstie L. Haywood等人在AS患者中探讨疲劳的频率和严重性以及相互间的关系,评价其对病情判断的价值和意义。研究结果发表在2014年3月的Rheumatology上。

在基线期,将参与者按照疲劳频率和程度分为4组。参与者在基线期和6个月的时候以邮寄的形式填写评价量表

在入组的AS患者中,基线期有451人出现疲劳症状,占被调查者的74%。其中有75%的AS患者常常感到疲劳且较严重,15%常有疲劳感但不严重,10%疲劳感严重但不频繁。

将AS患者按照性别、年龄或病程分组时,疲劳感在组间没有明显差异。自述常出现疲劳感且较严重的AS患者组与其他组相比,健康状态评估较差。自述常感到疲劳但不严重的AS患者与疲劳感严重但不频繁的AS患者评估结果相似,但结果比无疲劳感的AS患者差。

基线期无疲劳感和有频繁疲劳感且严重的AS患者分别有81%和79%在6个月后疲劳情况没有改变。然而,基线期仅频繁疲劳或疲劳感严重的AS患者有80%在6个月后得到改善,表现为43%无疲劳感或30%无频繁严重的疲劳感。

常规评价AS患者疲劳频率和严重程度对于理解其影响以及随着病程变化的情况非常重要。若不常规评估,则无法鉴别具有显着疲劳感的AS患者。而且,临床也亟待开发对疲劳症状多维度评估的有效手段。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2062494, encodeId=a211206249486, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun May 04 09:34:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043709, encodeId=36282043e09a5, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jun 04 22:34:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260796, encodeId=39e01260e9620, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 29 00:34:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444090, encodeId=63ee14440901d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Mar 29 00:34:00 CST 2014, time=2014-03-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2062494, encodeId=a211206249486, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun May 04 09:34:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043709, encodeId=36282043e09a5, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jun 04 22:34:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260796, encodeId=39e01260e9620, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 29 00:34:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444090, encodeId=63ee14440901d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Mar 29 00:34:00 CST 2014, time=2014-03-29, status=1, ipAttribution=)]
    2014-06-04 xue8602
  3. [GetPortalCommentsPageByObjectIdResponse(id=2062494, encodeId=a211206249486, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun May 04 09:34:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043709, encodeId=36282043e09a5, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jun 04 22:34:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260796, encodeId=39e01260e9620, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 29 00:34:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444090, encodeId=63ee14440901d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Mar 29 00:34:00 CST 2014, time=2014-03-29, status=1, ipAttribution=)]
    2014-03-29 tamgche
  4. [GetPortalCommentsPageByObjectIdResponse(id=2062494, encodeId=a211206249486, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sun May 04 09:34:00 CST 2014, time=2014-05-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043709, encodeId=36282043e09a5, content=<a href='/topic/show?id=6dd7211832f' target=_blank style='color:#2F92EE;'>#严重性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21183, encryptionId=6dd7211832f, topicName=严重性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jun 04 22:34:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260796, encodeId=39e01260e9620, content=<a href='/topic/show?id=493ee0559a7' target=_blank style='color:#2F92EE;'>#疲劳#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70559, encryptionId=493ee0559a7, topicName=疲劳)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=674961, createdName=tamgche, createdTime=Sat Mar 29 00:34:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444090, encodeId=63ee14440901d, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Sat Mar 29 00:34:00 CST 2014, time=2014-03-29, status=1, ipAttribution=)]
    2014-03-29 huagfeg

相关资讯

Ann Rheum Dis:阿达木单抗治疗中国成人AS患者安全有效

阿达木单抗在西方人群中治疗强直性脊柱炎(AS)患者的有效性已经得到证实,但在中国人群中的情况尚不清楚。来自中国人民解放军总医院的黄烽博士等在中国成人活动性AS患者中进行了一项随机、对照研究,此项研究第一次在中国人群AS患者中对阿达木单抗的安全性和有效性进行评估。 研究者在对至少一种非甾体类抗炎药耐受/反应不足的中国成人活动性AS患者中随机应用阿达木单抗40mg(229例)或相匹配的安慰剂(115

ARD:女性AS患者的病情更重、疗效更差

强直性脊柱炎(AS)是一种以炎性腰背痛、肌腱附着点炎及外周关节炎为主要特征的风湿免疫性疾病。既往认为,男性的发病率远高于女性。然而,最近一些研究发现,男女发病率之比仅为2-3:1。为明确性别因素是否对AS患者治疗中的临床症状、躯体功能及自我报告的疾病结局产生影响,来自荷兰阿姆斯特丹VU大学医学中心风湿免疫科的Irene E van der Horst-Bruinsma等人对四个对照性临床试验中的数

A&R:AS患者的背痛是一种包含有神经性疼痛在内的混合性疼痛

AS患者足背机械阈值和寒冷敏感性较健康对照组相比下降 AS患者的初级体觉皮质区、岛叶皮层、前扣带皮层、前中扣带皮层及辅助运动区的脑皮质变薄,而脑灰质的体积在丘脑及豆状核壳中增加 AS患者的疼痛检测积分与初级体觉皮质区脑灰质的减少相关,与运动皮质区、前扣带皮层、前额皮质、丘脑及纹状体中脑灰质的增加相关 强直性脊柱炎(AS)的病变主要累及中轴脊柱,是引起下腰背痛症状的常见疾病。为

胡大一:一切以降低患者终生CV风险为宗旨

《IAS 血脂异常全球诊治建议》中文版口袋书新闻发布会:胡大一教授 《IAS 血脂异常全球诊治建议》中文版口袋书现场签赠:胡大一教授     众多高度一致的研究奠定降低胆固醇减少事件理念 ——指南制定的基石 该建议开篇就旗帜鲜明地捍卫了百年胆固醇学说,指出没有胆固醇升高就没有冠心病及其他动脉粥样硬化性心血管疾病(ASCVD)。建议明确提到,众多高度

强直性脊柱炎合并髋关节受损的诊疗策略

强直性脊柱炎(AnkylosingSpondylitis,AS)是一种慢性炎症性疾病,主要侵犯骶髂关节、脊柱骨突、脊柱旁软组织及外周关节,引起炎性疼痛、晨僵、活动受限等症状,严重者可出现关节强直。同时可伴发关节外表现,包括眼葡萄膜炎、肠道炎症、指/趾炎、皮疹等,通常为单独出现或重叠存在,其中以眼和肠道的病变最为常见。根据累及部位和临床表现的不同,可将AS分为以脊柱关节受累为主的中轴型和以外周关节受

ACR:HAQ-S可用于AS患者外周关节受累的评价

强直性脊柱炎(AS)患者的功能受限可能是由于外周或者中轴关节受累。针对这一情况,来自美国国立卫生研究院,国立关节炎及肌肉骨骼及皮肤疾病的SIDDHARTH BETHI等人进行了一项研究,研究目的是明确Bath强直性脊柱炎功能指数(BASFI,一项基于中轴的评级方法)是否能检测出周围关节受累相关的功能受限;及修订的脊柱关节炎健康评估调查问卷(HAQ-S,一种基于周围关节的评价方法)是否能检测出中轴关